Skip to main content
SpringerLink
Log in

Behçet’s Disease

  • Chapter
Intraocular Inflammation

Abstract

Behçet’s disease (BD) is a relapsing multisystemic disorder with obliterative vasculitis affecting both arteries and veins including vasculopathy of capillaries. In 1937, Hulusi Behçet described oral aphthous ulcers, genital ulcers, and hypopyon uveitis as a triad.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aktulga E, Altac M, Muftuoglu A et al (1980) A double blind study of colchicine in Behçet’s disease. Haematologica 65:399–402

    CAS  PubMed  Google Scholar 

  2. Atmaca LS (1989) Fundus changes associated with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 227:340–344

    Article  CAS  PubMed  Google Scholar 

  3. Behçet H (1937) Über rezidivierende Aphthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157

    Google Scholar 

  4. Behçet’s disease: guide to diagnosis of Behçet’s di-sease. Behçet’s Disease Research Committee of Japan (1974) Jpn J Ophthalmol 18:291–294

    Google Scholar 

  5. BenEzra D, Atmaca LS (1999) Behçet’s disease. In: BenEzra D (ed) Ocular inflammation. Basic and clinical concepts. Martin Dunitz, London, pp 313–345

    Google Scholar 

  6. BenEzra D, Maftzir G, Kalichman I et al (1993) Serum levels of interleukin-2 receptor in ocular Behçet’s disease. Am J Ophthalmol 115:26–30

    Article  CAS  PubMed  Google Scholar 

  7. BenEzra D, Maftzir G, Barak V (1997) Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behçet disease. Am J Ophthalmol 123:593–598

    Article  CAS  PubMed  Google Scholar 

  8. Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339

    Article  PubMed Central  PubMed  Google Scholar 

  9. Sugi-Ikai N, Nakazawa M, Nakamura S et al (1998) Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet’s disease. Invest Ophthalmol Vis Sci 39:996–1004

    Google Scholar 

  10. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease (1990) Lancet 335:1078–1080

    Google Scholar 

  11. Deuter CM, Kotter I, Wallace GR et al (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136

    Article  CAS  PubMed  Google Scholar 

  12. Dilsen N (2003) The importance of the manifestations besides the ones included in international criteria for Behçet’s disease. Adv Exp Med Biol 528:105–108

    Article  PubMed  Google Scholar 

  13. Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A (1993) Comparative study of the skin pathergy test with blunt and sharp needles in Behçet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52:823–825

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Dilsen N, Konice M, Aral O (1986) Why Behçet’s disease should be accepted as a seronegative arthritis. In: Lehner T, Barnes CG (eds) Recent advances in Behçet’s disease. Royal Society of Medicine Services, London, pp 281–284

    Google Scholar 

  15. Fortune F, Walker J, Lehner T (1990) The expression of gamma delta T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behçet’s syndrome. Clin Exp Immunol 82:326–332

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Hamuryudan V, Ozyazgan Y, Hizli N et al (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774

    Article  CAS  PubMed  Google Scholar 

  17. Ishikawa S, Miyata M, Fujiwara N (1979) Experimental muco-enterogenital syndrome in pedigreed miniature swine (toxicological study). Excerpta Med Int Ser 467:53–57

    Google Scholar 

  18. Kaneko S, Suzuki N, Yamashita N et al (1997) Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet’s disease (BD) in Japan. Clin Exp Immunol 108:204–212

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Kari JA, Shah V, Dillon MJ (2001) Behçet’s disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 40:933–938

    Article  CAS  Google Scholar 

  20. Kontogiannis V, Powell RJ (2000) Behçet’s disease. Postgrad Med J 76:629–637

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Kotake S, Higashi K, Yoshikawa K et al (1999) Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 106:586–589

    Article  CAS  PubMed  Google Scholar 

  22. Kotter I, Durk H, Saal J et al (1996) Therapy of Behçet’s disease. Ger J Ophthalmol 5:92–97

    CAS  PubMed  Google Scholar 

  23. Kotter I, Koch S, Vonthein R et al (2005) Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 23:S20–S26

    CAS  PubMed  Google Scholar 

  24. Kotter I, Zierhut M, Eckstein A et al (2003) Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet’s disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 528:521–523

    Article  PubMed  Google Scholar 

  25. Krause L, Turnbull JR, Torun N et al (2003) Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s disease. Adv Exp Med Biol 528:511–519

    Article  CAS  PubMed  Google Scholar 

  26. Masuda K, Inaba G, Mizushima Y et al (1975) A nationwide survey of Behçet’s disease in Japan. Jpn J Ophthalmol 19:278–285

    Google Scholar 

  27. Masuda K, Nakajima A, Urayama A et al (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096

    Article  CAS  PubMed  Google Scholar 

  28. Matsumura N, Mizushima Y (1975) Leucocyte movement and colchicine treatment in Behçet’s disease. Lancet 2:813

    Article  CAS  PubMed  Google Scholar 

  29. Mishima S, Masuda K, Izawa Y et al (1979) The eighth Frederick H. Verhoeff Lecture. presented by Saiichi Mishima. Behçet’s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–279

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Mizushima Y, Matsuda T, Hoshi K et al (1988) Induction of Behçet’s disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15:1029–1030

    CAS  PubMed  Google Scholar 

  31. Mumcu G, Eragun T, Inanc N et al (2004) Oral health is impaired in Behçet’s disease and is associated with disease severity. Rheumatology (Oxford) 43(8):1028–1033

    Article  CAS  Google Scholar 

  32. Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825

    Article  CAS  PubMed  Google Scholar 

  33. Naganuma M, Funakoshi S, Sakuraba A et al (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10:251–257

    Article  PubMed  Google Scholar 

  34. Nakae K, Masaki F, Hashimoto T et al (1993) Recent epidemiological features of Behçet’s disease in Japan. In: Wechsler B, Godeau P (eds) Behçet’s disease. Excerpta Medica, Amsterdam, pp 153–158

    Google Scholar 

  35. Nakamura S, Sugita M, Tanaka S et al (1992) Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Behçet’s disease. Nippon Ganka Gakkai Zasshi 96:1282–1285

    CAS  PubMed  Google Scholar 

  36. Namba K, Sonoda KH, Kitamei H et al (2006) Granulocytapheresis in patients with refractory ocular Behçet’s disease. J Clin Apher 21:121–128

    Article  PubMed  Google Scholar 

  37. Niwa Y, Miyake S, Sakane T et al (1982) Auto-oxidative damage in Behçet’s disease – endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247–255

    PubMed Central  CAS  PubMed  Google Scholar 

  38. Nussenblatt RB, Palestine AG (1986) Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 31:159–169

    Article  CAS  PubMed  Google Scholar 

  39. Ohguro N, Yamanaka E, Otori Y et al (2006) Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol 141:218–220

    Article  CAS  PubMed  Google Scholar 

  40. Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368

    CAS  PubMed  Google Scholar 

  41. Ohno S, Ohguchi M, Hirose S et al (1982) Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol 100:1455–1458

    Article  CAS  PubMed  Google Scholar 

  42. Pervin K, Childerstone A, Shinnick T et al (1993) T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet’s disease. J Immunol 151:2273–2282

    CAS  PubMed  Google Scholar 

  43. Saylan T, Mat C, Fresko I, Melikoglu M (1999) Behçet’s disease in the Middle East. Clin Dermatol 17:209–223

    Article  CAS  PubMed  Google Scholar 

  44. Stuebiger N, Koetter I, Zierhut M (2000) Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet’s disease. Br J Ophthalmol 84:1437–1438

    CAS  PubMed  Google Scholar 

  45. Suzuki Y, Hoshi K, Matsuda T et al (1992) Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet’s disease. J Rheumatol 19:588–592

    CAS  PubMed  Google Scholar 

  46. Takeno M, Kariyone A, Yamashita N et al (1995) Excessive function of peripheral blood neutrophils from patients with Behçet’s disease and from HLA-B51 transgenic mice. Arthritis Rheum 38:426–433

    Article  CAS  PubMed  Google Scholar 

  47. The International study group for Behçet’s disease (1992) Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease-towards internationally agreed criteria. Br J Rheumatol 31:299–308

    Article  Google Scholar 

  48. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695

    Article  CAS  PubMed  Google Scholar 

  49. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380

    Article  PubMed  Google Scholar 

  50. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 50:256–265

    Article  PubMed  Google Scholar 

  51. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285

    Article  CAS  PubMed  Google Scholar 

  52. Yazici H, Tüzün Y, Pazarli H et al (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 43:783–789

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Yazici H, Yurdakul S, Hamuryudan V (1998) Behçet’s syndrome. In: Klippel JH, Dieppe PA (eds) Rheumatology, vol 2, 2nd edn. Mosby, London, pp 7.26.1–7.26.6

    Google Scholar 

  54. Yazici H, Yurdakul S, Hamuryudan V (1999) Behçet’s syndrome. Curr Opin Rheumatol 11:53–57

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Hokkaido University Graduate School of Medicine, N-15, W-7, Kita-ku, Sapporo, 060-8638, Japan

    Shigeaki Ohno MD, PhD, Kenichi Namba MD, PhD & Yuko Takemoto MD, PhD

Authors
  1. Shigeaki Ohno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenichi Namba MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Takemoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenichi Namba MD, PhD .

Editor information

Editors and Affiliations

  1. Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany

    Manfred Zierhut

  2. Biomedical Research Centre, Institute of Ophthalmology, Moorfields Eyes Hospital, Department of Medical Retina, UCL, London, United Kingdom

    Carlos Pavesio

  3. School of Medicine, Department of Ophthalmology, Hokkaido University Graduate, Sapporo, Hokkaido, Japan

    Shigeaki Ohno

  4. University of Belo Horizonte, Belo Horizonte, Brazil

    Fernando Orefice

  5. USC Eye Institute, University of Southern California, Los Angeles, California, USA

    Narsing A. Rao

1 Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Case Report 64

Behcet’s disease in an Indian patient (PPT 2762 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ohno, S., Namba, K., Takemoto, Y. (2016). Behçet’s Disease. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_66

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-75387-2_66

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-75385-8

  • Online ISBN: 978-3-540-75387-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation